.
The ubiquitin-proteasome system (UPS) has links to an expanding array of diseases, including cancer, immunological disorders and neurological disorders, and the validity of the UPS as a target has been confirmed by the clinical success of the proteasome inhibitor bortezomib (Velcade; Millennium Pharmaceuticals) in the treatment of multiple myeloma [5] [6] [7] . The success of bortezomib has driven the discovery and development of additional proteasome inhibitors for use as cancer therapeutics
, as well as the exploration of the potential use of proteasome inhibition for other diseases (mostly immune in nature, including graft-versus-host and autoimmune disease). Although bortezomib is clinically effective, multiple myelomas can evolve bortezomib resistance 8, 9 . Proteasome inhibitors also affect all processes that utilize ubiquitin-mediated degradation for regulation, and some side effects, such as neuropathy, have been reported 10, 11 . Additionally, debate remains about which molecular targets are crucial for the inhibition of tumour growth 10, 11 . However, the UPS is composed of more than 1,000 proteins, and there is the potential to develop more specific drugs that inhibit distinct biological processes with greater efficacy by choosing targets other than the proteasome itself (FIG. 1) . Indeed, in humans, there are two E1 ubiquitin-activating enzymes, multiple E2 enzymes and hundreds of E3 enzymes, which together control the degradation of thousands of substrates Ubiquitin A 76-amino acid protein that can be covalently conjugated to other proteins through amine groups at the amino terminus or on internal lysine residues. Proteins can be monoubiquitylated or polyubiquitylated. Chains assembled via K48 (in most cases) and K11 linkages target substrate proteins to the proteasome for degradation.
Ubiquitin-proteasome system
The ubiquitin-proteasome system (UPS) collectively refers to the proteins regulating ubiquitin-dependent protein degradation by the proteasome.
RING domains
Really interesting new gene (RING) domains coordinate zinc ions and often mediate binding of E2 ubiquitin conjugating enzymes.
Small-molecule inhibitors of E1 and E2 enzymes have been developed
, and similar to proteasome inhibitors, these drugs affect a vast range of substrates, which may limit their therapeutic value 11 (FIG. 1) . The UPS components that are viewed as the most promising drug targets are the DUBs and E3 ubiquitin ligases, which have fewer targets and provide the specificity of the system 4, 6 . Although targeted inhibition of the 95 DUBs is complicated by shared active sites (among only five classes of proteases) and a general lack of knowledge of the biological roles and regulation of these proteins (BOX 1 and reviewed elsewhere 4 ), several compounds that target E3 ligases with varying degrees of specificity have been developed. E3 enzymes can be divided into two main classes (RING or HECT E3 ligases), of which those with RING domains are the most common 14, 15 . RING-domain E3 enzymes mediate substrate ubiquitylation by bringing the substrate into contact with the E2 enzyme, whereas HECT domain E3 enzymes both recruit the substrate and directly participate in the ubiquitin transfer reaction. RING-domain E3 ligases can function as single sub unit enzymes or as multisubunit enzymes. Multisubunit RING-domain E3 enzymes, such as the cullin (CUL)-RING ligases (CRLs), allow one core scaffold to facilitate the ubiquitylation of numerous substrates via variable or exchangeable substrate recognition modules 16 . Notably, the large number of ubiquitin ligases and ubiquitin ligase substrates links the UPS to numerous different biological pathways and functions, many of which are dysregulated in a wide range of diseases. Therefore, the abundance and diversity of ubiquitin ligase-substrate pairs offers the potential for the development of drugs that are highly specific at both the pathway and protein scales. This Review discusses the rationale and approaches to targeting a large family of E3 ubiquitin ligases, the S-phase kinase-associated protein 1 (SKP1)-CUL1-F-box protein (SCF; also known as CRL1) complexes, with novel therapeutics, using established model systems to highlight key concepts and principles.
SCF ubiquitin ligases
Cullins. In mammals, there are eight cullin proteins that form the backbone of approximately 200 CRLs, of which SCF complexes are the best characterized. Each CRL complex contains a different cullin subunit that acts as an extended scaffold that simultaneously binds to the catalytic machinery (E2 ubiquitin-conjugating enzymes) at the carboxyl terminus and substrate recognition factors at the N terminus. The C termini of CUL1, CUL2, CUL3, CUL4A, CUL4B, CUL7 and CUL9 bind to the E2 enzyme via the small RING protein, RING-box protein 1 (RBX1), whereas CUL5 uses the related protein RBX2 for E2 recruitment 16 . In addition to recruiting the E2 enzyme for substrate ubiquitylation, the RBX proteins recruit the E2 enzyme required for the covalent attachment of NEDD8, a small ubiquitin-like protein, to the cullin backbone (FIG. 2) . Neddylation induces a structural re arrangement in the cullin backbone that facilitates ubiquitin transfer from the E2 enzyme to the substrate and is required for CRL function. Similar to ubiquitylation, this modification results from the sequential action of NEDD8-specific E1, E2 and E3 enzymes (the RBX-cullin complexes themselves) 12, 16 , and can be reversed via the actions of the COP9 signalosome (reviewed elsewhere) 17 . The N terminus of each cullin protein binds and uses a unique family of proteins for substrate specification, and the large number of adaptor proteins that can be utilized enables the assembly of more than 200 different CRLs from the eight cullin scaffolds. The N terminus of CUL1 interacts with SKP1, which binds to the F-box domain of an interchangeable F-box protein 6 (FIG. 2) . The F-box domain is an approximately 40 amino acid domain, which was originally defined in cyclin F (CCNF; also known as FBXO1). There are 69 F-box proteins in humans, classified into three families based on their protein interaction domains: WD40 domains (10 F-box and WD repeat domain containing (FBXW) proteins), leucine-rich repeats (21 F-box and leucine-rich repeat (FBXL) proteins) and those with other, diverse, domains (38 F-box (FBXO) proteins) 18 . These proteinprotein interaction domains interact with specific substrates. Most of the well-studied F-box proteins have multiple substrates 19 . Therefore, it is thought that each F-box protein will have multiple substrates, making the full complement of SCF substrates immense. Ubiquitin (Ub) is attached to substrates by the consecutive activities of three enzymes. An E1 enzyme activates ubiquitin in an ATP-dependent reaction. An E2 enzyme subsequently transfers the activated ubiquitin to the substrate that is specifically bound to the E3 substrate selection factor. Polyubiquitylated substrates are targeted to the proteasome, a multisubunit protease, to undergo degradation. Although protein degradation is irreversible, the ubiquitylation signal can be attenuated through the action of deubiquitylating enzymes (DUBs). Multiple enzymatic steps within the ubiquitylation process are potentially druggable. According to selectivity factors, E3 ubiquitin ligases represent the most specific point of intervention. By contrast, proteasome inhibitors block the degradation of numerous substrates.
HECT domain
Homologous to E6 carboxy-terminus (HECT) domains define a sub-family of E3 ubiquitin ligases. HECT domains recruit the E2 ubiquitin conjugating enzyme and participate directly in substrate ubiquitylation by forming a thioester bond with ubiquitin.
Cullin (CUL)-RING-ligases
(CRLs). A family of multisubunit E3 ubiquitin ligases that share a common architecture. The eight CRLs are each based on a different cullin scaffold protein, and each complex recruits a small RING protein and a unique set of substrate adaptor proteins.
SCF complexes
(SKP1-CUL1-F-box protein complexes; also known as CRL1). A family of multi-subunit E3 ubiquitin ligases. As listed in the name, SCF complexes contain a cullin 1 (CUL1) scaffold, and an S-phase kinase-associated protein 1 (SKP1) that bridges CUL1 to a variable F-boxcontaining protein, of which there are ~70 in mammals. These complexes also contain the small RING protein RBX1.
NEDD8
A small, ubiquitin-like protein that can be conjugated to other proteins to alter their function. The best-defined and most abundant substrates for neddylation are the cullin family of proteins, which require neddylation for their activity.
Box 1 | Drugging the ubiquitin-proteasome system
The ubiquitin-proteasome system (UPS) can be targeted with therapeutics at multiple levels, resulting in varying degrees of specificity (FIG. 1) . For example, proteasome inhibitors globally inhibit the degradation of all proteins, whereas E3 ubiquitin ligase inhibitors will block the degradation of a small subset of proteins. Compounds affecting each point in the UPS have been explored. Although some of these compounds remain experimental, others have advanced into preclinical and clinical trials.
Proteasome inhibition
Broad inhibition of all ubiquitin-dependent degradation by the proteasome inhibitor bortezomib is clinically effective in the treatment of multiple myeloma and relapsed mantle cell lymphoma. The proteasome features three dominant proteolytic activities (chymotrypsin-like, trypsin-like and peptidyl-glutamyl peptide hydrolysing), as well as two less-well-characterized proteolytic activities (branched chain amino acid-preferring and small neutral amino acidpreferring) 138 . Most of the proteasome inhibitors in clinical trials inhibit the chymotrypsin-like and/or trypsin-like activities of the proteasome.
Although proteasome inhibition stabilizes antiproliferative proteins, part of the effectiveness of proteasome inhibitors is thought to be due to the general exacerbation of the proteotoxic stress found in tumour cells, particularly antibody-secreting plasma cells, which produce large amounts of immunoglobulins 10 . Following the success of bortezomib, several other proteasome inhibitors, including ixazomib, delanzomib, marizomib and oprozomib, are currently in various stages of clinical trials, and carfilzomib has been approved for the treatment of multiple myeloma 9, 139 .
p97 AAA+ ATPase inhibitors
The p97 AAA+ ATPase facilitates the degradation of chromatin-, endoplasmic reticulum-and mitochondria-associated proteins through the extraction and/or unfolding of ubiquitylated proteins, therefore regulating the degradation of multiple proteins involved in a broad range of disease-associated processes 140, 141 . p97 also plays a key role in the regulation of cullin-ring ligase (CRL) assembly 142, 143 . Several p97 inhibitors are in preclinical studies and/or poised to enter Phase I trials 144, 145 .
Ubiquitin E1 enzyme inhibitors
There are two human E1 enzymes, UBA1 and UBA6, and the success of proteasome inhibitors has suggested that broad inhibition of protein ubiquitylation by these enzymes would have antiproliferative effects 11, 146 . The small-molecule compound PYR-41 covalently binds and irreversibly inhibits UBA1, confirming the antiproliferative effects of broad ubiquitylation inhibition; several additional E1 enzyme inhibitors are in preclinical testing 147, 148 . Cross-reactivity of UBA1 inhibitors with UBA6 has not been reported. Inhibiting global ubiquitylation might be expected to produce broad biological effects because such broad inhibition would inhibit both ubiquitin-dependent degradation and ubiquitin-mediated signalling.
NEDD8 E1 enzyme inhibitors
Similar to ubiquitylation, neddylation, the covalent attachment of NEDD8 to other proteins, utilizes a cascade composed of an E1, an E2 and an E3 enzyme 39 . As its name implies, ubiquitin modification is nearly ubiquitous, but NEDD8 modification is substantially more selective. The best known NEDD8 targets are the cullins, and neddylation is required for their ubiquitin ligase activity. Because cullins regulate many proteins involved in cell proliferation, inhibition of neddylation is an attractive target for cancer chemotherapy. MLN4924 was the first reported neddylation inhibitor, and it inhibits neddylation at the level of the E1 enzyme 35, 39 . In preclinical testing, MLN4924 was a potent antiproliferative agent, and it has now completed Phase I trials. Although the effects of MLN4924 are reported to be mediated through inhibition of chromatin licensing and DNA replication factor 1 (CDT1) degradation, it is likely that disruption of the degradation of other CRL substrates contributes to its effectiveness.
E2 enzyme inhibitors
There are approximately 40 E2 enzymes, suggesting that inhibition of E2 enzymes could provide inhibition of ubiquitylation that is slightly more specific than the global inhibition of an E1 enzyme inhibitor. However, E2 enzymes can still control the degradation of many substrates. Thus far, one specific allosteric inhibitor of cell division cycle protein 34 (CDC34) has been reported, and this inhibitor, which binds a pocket between the E2 enzyme and the covalently linked ubiquitin, does not interfere with either E1 or E3 enzyme binding 149, 150 . For the purposes of this Review, inhibitors that block E2-E3 binding are considered to be E3 inhibitors.
DUB inhibitors
Because they directly regulate the stability of substrates by counteracting ubiquitylation, deubiquitylating enzymes (DUBs) are prime targets for the development of inhibitors. There are approximately 100 different DUBs, offering the potential to inhibit a narrow range of biological functions, and, as proteases, the active sites of DUBs are amenable to traditional small-molecule competitive inhibitors 4 . In particular, ubiquitin-specific peptidase 7 (USP7), which regulates MDM2 and p53, is under investigation, and USP7 inhibitors increase p53 levels 151, 152 . A selective USP14 inhibitor also increases proteasome activity and may be useful in pathologies characterized by proteotoxic stress and accumulation of ubiquitylated proteins [153] [154] [155] . However, the development of DUB inhibitors has been impeded by several issues, including a general lack of knowledge of DUB functions and a lack of specificity in competitive inhibitors. For example, one of the most promising DUB inhibitors derives its antiproliferative activity from inhibition of both USP7 and USP47 (REFS 156, 157) . Another DUB inhibitor non-selectively inhibits USP5, USP14, UCH37 and USP9X
158
. Non-competitive inhibitors of USP1, the deubiquitinase for proliferating cell nuclear antigen (PCNA), and Fanconi anaemia, complementation group D2 (FANCD2) and group I (FANCI), have been characterized 159 . However, the development of non-competitive inhibitors is complicated by the lack of understanding of the biochemical mechanisms of DUBs, particularly the involvement of cofactors and other regulatory proteins [160] [161] [162] [163] . Nature Reviews | Drug Discovery F-box protein-substrate recognition. The F-box proteins typically recognize unique, short degradation motifs (termed degrons) in their substrates. In many of the well-characterized F-box protein-substrate interactions, post-translational modifications (often phosphorylation) of the substrate's degron direct F-box protein binding, and although unmodified degrons exist, access to these degrons is usually controlled by post-translational modifications or other regulatory mechanisms 6 . The protein interaction domains in F-box proteins are highly specific degron recognition domains, often recognizing short peptide sequences. For example, SKP2 (also known as FBXL1), together with its cofactor cyclin-dependent kinase subunit 1 (CKS1; also known as CKS1B), recognizes p27 (also known as CDKN1B) only after it is phosphorylated on Thr187 by a cyclin-dependent kinase (CDK) [20] [21] [22] [23] . However, it is becoming increasingly clear that F-box proteins can recognize a wide variety of degrons, allowing multiple alternative mechanisms to dictate substrate selection. For example, in addition to phosphorylations, F-box proteins can recognize glycosylated or non-modified degrons 6 . Some degrons are even protected by phosphorylations that block F-box protein binding, such as the degrons within chromatin licensing and DNA replication factor 2 (CDT2; degraded via SCF FBXO11 ) and p85β (also known as PIK3R2; degraded via SCF FBXL2 ) [24] [25] [26] . Moreover, F-box proteins themselves are tightly regulated by post-translational mechanisms, including phosphorylation and proteolytic turnover. The distinct modes of substrate recognition by F-box proteins have been thoroughly discussed previously 6 .
Targeting E3 enzymes
In the past 20 years, the pharmaceutical industry has focused a considerable amount of effort on the discovery and development of protein kinase inhibitors [27] [28] [29] [30] , and this effort to develop kinase inhibitors offers a framework for the development of ubiquitin-ligase-based therapies
. However, ubiquitin ligase complexes have biochemically distinct active sites -in addition to other potential drug binding pockets -that offer multiple targets for small molecules, suggesting that ubiquitin-ligase-focused therapies could achieve greater specificity than competitive kinase inhibitors. Notably, the protein-protein interaction surfaces required for both SCF assembly and substrate recognition are of sufficient size to accommodate many potential compounds (and are not too large for a small-molecule approach to therapies) 31 . Conversely, this distinctiveness of ubiquitin ligase active sites also creates substantial hurdles to drug development because the unique features of each ligase must be known and compounds cannot be simply generated from a common molecular backbone for all ubiquitin ligases. These limitations are similar to those observed in the development of non-competitive kinase inhibitors and of inhibitors of protein-protein interactions and have considerably impeded the development of these drug classes.
Non-SCF ubiquitin ligases as drug targets. The promise of specific E3 ubiquitin ligase inhibitors has been confirmed by the nutlins, a class of small-molecule inhibitors of the MDM2 ubiquitin ligase, which have completed Phase I clinical trials 32 (TABLE 1) . The activation of the tumour suppressor p53 (also known as TP53) to block cell proliferation or induce apoptosis of tumour cells is a primary goal in the treatment of p53-positive tumours, and nutlins inhibit the interaction of MDM2 with p53, thereby stabilizing p53. However, because p53 is the primary antitumour effector, theoretically nutlins should only be effective in the context of wild-type p53, and therefore require prior knowledge of the p53 status of the tumour. Nutlins, the general name given to a series of similar compounds based on a cis-imidazoline backbone, are competitive inhibitors of p53 binding to MDM2, and these compounds structurally mimic Figure 2 | The modular structure of SCF ubiquitin ligases and points of potential therapeutic intervention. Cullin 1 (CUL1) acts as a scaffold protein that brings the E2 enzyme in close proximity to the substrate. It binds to S-phase kinase-associated protein 1 (SKP1) at its amino terminus, and the E2 enzyme via RING-box protein 1 (RBX1) at its carboxyl terminus. The F-box protein functions as the interchangeable component (69 F-box proteins are known in humans) that interacts with SKP1 via its F-box domain and with its cognate substrate through its specific substrate recognition domain. CUL1 is activated by covalent conjugation with NEDD8. This modification induces a conformational change in CUL1 that facilitates the transfer of ubiquitin (Ub) from the E2 enzyme to the substrate and is required for cullin-ring ligase (CRL) function. MLN4924, a small-molecule inhibitor of the NEDD8 enzyme, shows therapeutic potential and has completed Phase I clinical trials. Because MLN4924 inhibits the activity of all CRLs, it affects the degradation of numerous substrates. Strategies to inhibit SKP1-CUL1-F-box protein (SCF) ligase function with more selectivity include blocking SCF complex assembly, blocking the interaction between the substrate and the F-box protein, and inhibiting E2 enzyme binding and/or function.
interactions of p53 (through the amino acids Phe19, Trp23 and Leu26) with the N terminus of MDM2 (REF. 33 ). In general, nutlins are active in both cell culture and xenograft model systems, resulting in p53 accumulation, apop tosis and tumour regression. Phase I trials of the nutlin RG7112 were recently completed, and this compound demonstrated activation of the p53 pathway, including the induction of apoptosis, suggesting its potential as a single agent therapy 34 . Several additional nutlins and nutlin-like compounds are being evaluated in ongoing Phase I studies.
Although the inhibition of a single ubiquitin ligase by nutlins offers an argument for specificity, it is also possible to generate effective chemotherapies targeting multiple E3 ubiquitin ligases. The CRL family of ubiquitin ligases has multiple links to cancer, with CRL1 and CRL4 having particularly strong links owing to their control of the cell cycle, DNA replication and DNA repair. As discussed above, the activity of CRLs is dependent on the modification of their cullin backbones by the small ubiquitin-like protein NEDD8 (REF. 16) (FIG. 2) . MLN4924, which inhibits cullin neddylation, was shown to be an effective antiproliferative agent, and, thus far, the results from this drug in preclinical studies have been promising in various cancers 35 . MLN4924 inhibited the growth of lung, ovarian, breast, leukaemia, lymphoma, myeloma, melanoma, and Ewing's sarcoma cells in vitro, and this broad spectrum of effectiveness was also supported by experiments in xenograft and transgenic rodent models [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] . Phase I trials of MLN4924 in lymphoma, myeloma and melanoma have been completed, and multiple other Phase I trials are ongoing. The antitumour effect of MLN4924 was initially ascribed to the inhibition of SCF and/or CRL4-dependent degradation of CDT1. However, similar to proteasome inhibition, MLN4924 must affect a broad range of substrates that are targeted for degradation through the more than 200 CRL complexes 35, [46] [47] [48] . The potential impact of MLN4924 through other reported non-cullin NEDD8 substrates is unclear 49 . Notably, the evolution of resistance to MLN4924 has been observed in vitro 50, 51 .
Box 2 | Lessons learnt from kinase inhibitor development and application
In terms of rationale, an extensive body of literature links both the deregulation of kinases and ubiquitin ligases to many diseases, including cancer and immunological disorders, and this knowledge has established key mechanisms, regulators and pathways. Additionally, both families of kinases and ubiquitin ligases are large and have many substrates: there are more than 500 kinases and more than 700 ubiquitin ligases encoded in the human genome, offering the promise of specific action through the inhibition of individual proteins.
There are also notable differences that affect the ability to effectively target kinases and ubiquitin ligases with novel therapeutics 164 . With respect to drug development, the most important difference is the nature of each enzyme's active site. Kinase active sites bind ATP, and so many ATP analogues have been developed as competitive inhibitors. However, because all kinases utilize ATP, kinase active sites are often structurally similar so these competitive inhibitors often inhibit multiple kinases and/or exhibit a narrow therapeutic dose window for specific inhibition 28 . In some cases, this lack of specificity may add to the clinical efficacy by inhibiting multiple kinases in signalling cascades, such as has been observed with the successful use of sorafenib 30 , whereas in other cases greater specificity is required in subsequent generations of compounds. The ubiquitylation reactions catalysed by ubiquitin ligases do not share any small metabolites, such as ATP, and each active site for these enzymes is uniquely defined by the proteinprotein interactions of the ubiquitin ligase and the substrate, thereby avoiding the specificity issues of ATP analogues used in competitive kinase inhibitors 28 . Notably, although non-competitive inhibitors of kinases can be developed, including allosteric inhibitors, protein-protein interaction inhibitors or antibody-based therapies that target receptor tyrosine kinases, a primary focus has been on small-molecule, competitive inhibitors based on ATP analogues that bind kinase active sites, such as imatinib, dasatinib, sorafenib, palbociclib and idelalisib, all of which are clinically effective or look extremely promising in late-stage clinical trials 30, [164] [165] [166] [167] [168] [169] [170] . The development of cyclin-dependent kinase (CDK) inhibitors illustrates both the successes and failures of developing competitive kinase inhibitors. Because CDKs are key components of the machinery driving the cell cycle, inhibition of CDK1, CDK2, CDK4 or CDK6 should block cell proliferation. Indeed, the first generation CDK inhibitors, such as flavopiridol and roscovitine, are effective inhibitors of kinase activity and have a clear antiproliferative effect in vitro. However, the antiproliferative activity of these CDK inhibitors may actually stem from their inhibition of transcription and induction of apoptosis through CDK7, CDK8 and CDK9 (REF. 171 ). Importantly, the first-generation inhibitors have had limited success in the clinic and only in the context of multiple-agent therapy. More selective, next-generation CDK inhibitors, such as palbociclib, which specifically inhibits CDK4 and CDK6, may prove to be more efficacious, especially when coupled with a more advanced molecular genetic understanding of individual tumours. For example, a primary target of investigation for palbociclib is breast cancer, a disease with clear links to the activation of cyclin D-CDK4 and possibly cyclin D-CDK6.
Although the development of CDK inhibitors may suggest that specific kinases inhibitors are best, current treatments for chronic myelogenous leukaemia (CML) demonstrate that both highly specific and less specific kinase inhibitors can be clinically effective. Imatinib, the frontline therapy for CML, was developed as a specific inhibitor of the BCR-ABL fusion protein that drives CML. When CML becomes resistant to imatinib, dasatinib can be an effective therapy, and unlike imatinib, which is highly specific for BCR-ABL, KIT and platelet-derived growth factor receptor, dasatinib also inhibits all nine of the SRC family kinases, as well as several other tyrosine kinases 28 . The utilization of these kinase inhibitors in CML demonstrates that both specificity and context are important in the application of kinase inhibitor therapies, and broad inhibition of multiple pathways can be an effective strategy.
SCF ubiquitin ligases as drug targets. The success of MLN4924 and our extensive knowledge of cancer-relevant CRL targets -particularly for SCF ligases -suggest that, at least in some cases, the specific inhibition of individual CRLs may prove to be more effective and provide a better therapeutic index than global inhibition via MLN4924. Additionally, although initial efforts targeting the UPS have focused on the development of anticancer therapeutics, our expanding knowledge of the SCF family of ubiquitin ligases indicates that the targeting of specific SCF complexes may also result in effective therapies for various disorders, including sleep disorders, mood disorders, inflammation and acquired infections [52] [53] [54] [55] [56] [57] [58] [59] .
Although many F-box protein-substrate pairings have been described and linked to potential biological functions, the first hurdle to generating SCF-directed therapies remains the thorough biological characterization of the family. Less than 20 of the 69 F-box proteins have established substrates, and even fewer F-box proteins have multiple confirmed substrates from which key biochemical principles for substrate targeting and ubiquitylation can be extrapolated 6, 19 (TABLE 2) . Additionally, although some F-box proteins appear to have a universal function (that is, either driving or stopping cell proliferation) by targeting substrates with common biological functions, other F-box proteins control substrates βTrCP, β-transducin repeat-containing protein; Cdc4, cell division control protein 4; CKS1, cyclin-dependent kinase subunit 1; CRBN, cereblon; CRY2, cryptochrome 2; FBXL3, F-box and leucine-rich repeat protein 3; FBXO3, F-box protein 3; IκBα, nuclear factor-κB inhibitor-α; N/A, not applicable; PDCD4, programmed cell death 4; RBX1, RING-box protein 1; SCF, SKP1-CUL1-F-box protein; SKP, S-phase kinase-associated protein.
Pharmacophores
The features of a small-molecule ligand that dictate the interactions with macromolecular targets that are responsible for its biological activities.
with disparate, or even opposing, biological functions. Therefore, a thorough understanding of the role of each F-box protein is essential for determining targets and/or targeting strategies. Finally, the majority of studies of SCF function have focused on roles in cancer 5, 60, 61 , and more research is required to define the roles of these proteins in other diseases.
Despite these caveats, there are multiple SCF complexes with defined biology and biochemistry and clear links to human disease, and these SCF complexes illustrate the key concepts of targeting SCF complexes with novel therapies (TABLE 2) . Direct modulation of SCF activity in diseases typically results from the over expression or mutation (deletion or point mutation) of an F-box protein, and indirect modulation typically affects pathways controlling degron modifications or substrate degrons themselves. Each mechanism requires a different conceptual approach for the development of therapeutics.
Inhibition of SCF-mediated degradation SKP2-mediated p27 degradation. SKP2 is one of the best-characterized F-box proteins and a verified oncoprotein in multiple tumours and animal models [62] [63] [64] . Together with the cofactor CKS1, SKP2 promotes S-phase entry by mediating the ubiquitylation and degradation of the CDK inhibitor p27, an important tumour suppressor 20, 21, 65 . Notably, p27 is seldom mutated in cancer, and its tumour-suppressive activity is typically removed by SKP2 overexpression. Accordingly, SKP2 overexpression correlates with high tumour grade and poor prognosis in multiple cancers 5 . Other SKP2 targets, including the p57 (also known as CDKN1C) and p21 (also known as CDKN1A) CDK inhibitors, may also be relevant to SKP2 overexpression in cancer 61 . However, in mouse models, SKP2 overexpression is phenocopied by p27 deletion, and Skp2-knockout phenotypes are rescued by p27 deletion, suggesting that the oncogenic functions of SKP2 are largely dependent on p27 degradation 62, 64 . Thus, SKP2 presents an attractive target for the generation of inhibitors of p27 degradation.
The biochemistry of the SKP2-CKS1-p27 interaction is well established. Binding of SKP2 and CKS1 to p27 is controlled by phosphorylation of the degron by a CDK, and the crystal structure of SKP2, CKS1 and the p27 phosphodegron clearly shows a pocket between SKP2 and CKS1 that is flanked by residues essential for p27 binding [20] [21] [22] [23] 66 . This thorough understanding of SKP2-dependent p27 degradation can facilitate the development of inhibitors of p27 degradation, which could target the SKP2-CKS1 degron interface or structural features of the SCF SKP2 complex (FIGS 2,3; TABLE 1). Indeed, inhibitors that target both features were recently reported. These compounds were identified via in silico screens using the structure of SCF SKP2 and validated in vitro and in tissue culture systems. One group identified small-molecule compounds that could bind the interface between SKP2, CKS1 and p27 and disrupt complex formation 67, 68 . Another in silico screen identified a SKP2 inhibitor, compound #25, that interfered with the binding between SKP2 and SKP1, thus preventing the formation of an active SCF complex 69 . A mechanistically similar inhibitor of the yeast F-box protein Met30 was previously identified in a screen for rapamycin sensitivity, and although both this compound and compound #25 might be expected to inhibit multiple F-box proteins by binding the F-box domain and blocking SKP1 binding, each compound seems to be specific for only one F-box protein 69, 70 . The described compounds, whether targeting the F-box protein-substrate interface or the F-box-protein-SKP1 interface, are effective at relatively high concentrations. However, one key advantage of the in silico approaches to generating SKP2 inhibitors is that the potency of lead compounds identified by virtual screens can be optimized via traditional medicinal chemistry with a priori knowledge of the important molecular contacts and pharmacophores. Thus far, the in silico approaches to inhibiting SKP2 have focused on directly disrupting either p27 or SKP1 binding, but it may also be possible to generate allosteric inhibitors of SKP2 (FIG. 3) . For example, an allosteric inhibitor that binds the WD40 repeats of the yeast F-box protein cell division control protein 4 (Cdc4) and causes structural rearrangements that block substrate binding was identified through a more traditional in vitro screen 71 . Traditional screening approaches for the development of inhibitors of p27 degradation have failed to identify compounds that directly affect SCF SKP2 (REFS 72-74). It is unclear why traditional screens, such as those dependent on p27-degron reporter fusions, have so far failed to detect compounds that directly disrupt SKP2 interactions, but multiple reasons, including the limited number of compound libraries screened and cell permeability issues, may reduce the identification rate for lead compounds of this class. In other cases, cell-based screens have detected compounds that reduce SKP2 mRNA levels and do not directly affect the activity of SCF SKP2 towards p27 (REF. 74 ). However, traditional screens do efficiently identify small-molecule inhibitors of CDKs as inhibitors of the SKP2-p27 interaction, highlighting another key concept for the inhibition of SCF ubiquitin ligases 75 . Because the binding of many F-box proteins to their consensus degrons requires phosphorylation of the degron, inhibition of kinases or other modifying proteins represents a viable option for the inhibition of substrate degradation, and this indirect method of inhibition can make use of many pre-existing compounds, such as kinase inhibitors (see below) 75, 76 . Overall, it is likely that a combination of in silico and traditional screening approaches will prove more successful than the application of either individually.
SKP2-mediated p27 degradation is the paradigm for the development of SCF-targeted inhibitors because of our extensive understanding of the biochemistry, a highquality crystal structure and an established link to disease. However, several other F-box proteins represent intriguing targets for the development of inhibitors (TABLE 2) . Although the biochemistry of substrate degradation by these F-box proteins is incompletely understood and firm links to disease may not yet be established, several features of these F-box proteins underscore their potential as drug targets.
Cryptochrome proteins
The two mammalian cryptochrome proteins (cryptochrome 1 (CRY1) and CRY2) function in the circadian clock machinery as transcriptional repressors.
FBXL3. FBXL3 controls circadian rhythm oscillations through the degradation of cryptochrome proteins (cryptochrome 1 (CRY1) and CRY2) [77] [78] [79] . Abnormalities in the circadian machinery are linked to sleep disorders, mood disorders and various metabolic disorders, suggesting that pharmacological manipulation of circadian rhythms could be of therapeutic value. Our rapidly evolving understanding of the biochemistry of FBXL3-mediated CRY degradation presents several opportunities for drug development. The X-ray crystal structure of the FBXL3-CRY2 complex was recently solved, revealing several key features of this interaction 80 . FBXL3 binds CRY2 across an extended region through its leucine-rich repeats (LRRs). Additionally, the conserved tail of FBXL3 protrudes abruptly from the arch-like LRR domain and inserts into a deep pocket in CRY2. Intriguingly, this conserved pocket binds the redox factor FAD, raising the possibility that FAD or FAD analogues may function as competitive inhibitors of FBXL3 binding to CRY proteins. Indeed, a small, FAD-like molecule (KL001) that lengthens the circadian cycle was previously identified in a screen 81 , and this drug has now been shown to occupy the CRY2 cofactor pocket, probably blocking insertion of the tail of FBXL3 (REF 82) , thus impairing the ability of FBXL3 to bind to CRY2 and mediate its ubiquitylation.
This detailed understanding of FBXL3-mediated CRY degradation -and the means to inhibit this degradation via FAD analogues -has outpaced our current understanding of the potential roles of CRY in disease. This discrepancy illustrates a key issue for the SCF ligase field in the future. Historically, SCF ligase research has focused on cancer and cell proliferation, and although it is clear that F-box proteins will regulate many other processes, research into these areas has lagged. Additionally, although inhibition of FBXL3 may be advantageous in terms of circadian regulation and disorders associated with CRY dysregulation, there could be other FBXL3 βTrCP, β-transducin repeat-containing protein; CKS1, cyclin-dependent kinase subunit 1; CRY2, cryptochrome 2; CUL1, cullin 1; FBXW7, F-box and WD repeat domain containing 7; FBXL, F-box and leucine-rich repeat protein; FBXO, F-box protein; HCV, hepatitis C virus; RBX1, RING-box protein 1; SCF, SKP1-CUL1-F-box protein; SKP, S-phase kinase-associated protein; TRF1, telomeric repeat binding factor 1.
Hepatitis C virus (HCV) NS5A
A multifunctional protein generated from the cleavage of a polyprotein precursor during HCV infection and required for productive HCV infection. substrates that affect unknown processes; therefore, the overall biological effects of some classes of FBXL3 inhibitors may be more pleiotropic than others. Also, KL001 is an analogue of a common metabolite, and therefore may influence other pathways. However, it is intriguing that KL001, through its stabilization of CRY, is able to inhibit glucagon-induced gluconeogenesis in hepatocytes in cell culture 81 , hinting that inhibition of CRY degradation might be utilized beyond the regulation of sleep-wake cycles in the treatment of diabetes and metabolic disorders.
Proteolysis targeting chimeras (PROTACs

FBXL2.
Although the FBXL3-CRY interaction has firm biochemistry and relatively weak links to disease, there is a strong foundation to support the development of FBXL2 inhibitors from a disease perspective despite a lack of complete biochemical information. FBXL2 is one of two F-box proteins featuring CAAX motifs, which direct its geranylgeranylation and subsequent localization to cell membranes. This membrane localization seems to be required for phosphoinositide 3-kinase (PI3K) activation through FBXL2-mediated degradation of p85β 26 . FBXL2 also binds to the hepatitis C virus (HCV) NS5A protein, and an undefined, SCF-and localization-dependent activity of FBXL2 is required for the replication of HCV 52 . Notably, HCV was previously observed to require geranylgeranylated host proteins, which may be a reflection of this requirement for FBXL2 function 83 . However, this idea requires clear demonstration, and although NS5A is not a target for FBXL2, the relevant targets of FBXL2 in the context of HCV infection remain unclear. Despite the recent development of effective HCV therapies, FBXL2 offers a distinct new target to counter the evolution of resistance to current drugs, and novel HCV therapies may prove more economical 84, 85 . The development of FBXL2 inhibitors is challenging because the biochemistry of FBXL2-mediated degradation remains unclear, irrespective of HCV infection. Several potential FBXL2 substrates have been identified, but the degradation of these substrates has not been linked to HCV replication 26, [86] [87] [88] [89] . It is also unknown whether NS5A enhances ubiquitylation of normal FBXL2 substrates or retargets FBXL2 to novel substrates. In the context of uninfected cells, the limited number of reported FBXL2 substrates does not support a consensus mechanism for understanding the biochemistry of FBXL2-mediated degradation, and there is no crystal structure available. Therefore, although there is a strong rationale for developing FBXL2 inhibitors for the treatment of HCV, insufficient biochemical detail is available to support the development of effective inhibitors. As with other F-box proteins, FBXL2 has multiple substrates, and FBXL2-targeted therapies might have effects beyond limiting HCV infection. Therefore, the best FBXL2-targeted therapies may focus on the binding between FBXL2 and NS5A, instead of interactions with the substrate or SCF scaffold, although further investigation of FBXL2 functions in the absence of HCV infection may suggest the application of additional FBXL2 inhibitors in settings beyond HCV infection 26, 86, 88, 90 .
Retargeting the F-box protein-substrate interface Inhibitors of SCF ligase function are needed for pathologies resulting from F-box overactivity or overexpression, such as SKP2 in tumours. However, it is often the loss of F-box protein activity that leads to disease, and in these situations the function of a defective SCF ligase must be restored, presenting a different set of problems for generating effective therapies (FIG. 3) . FBXW7 is a wellestablished tumour suppressor in various tissues 60, [91] [92] [93] [94] . The majority of FBXW7 substrates are oncoproteins, including cyclin E, MYC, Notch and JUN (reviewed in REF. 60 ). FBXW7 is located at a genomic region that is frequently deleted in tumours, and it is estimated that 6% of all cancers have mutations in the FBXW7 gene [95] [96] [97] . It is mutated most frequently in T-cell acute lymphoblastic leukaemia (31%) and cholangiocarcinomas (35%), but is also frequently mutated in colorectal cancer (17%), endometrial cancers (16%), bladder cancers (10%) and lung squamous cell carcinomas (6%). FBXW7 mutations are also observed in gastrointestinal and prostate cancers. FBXW7 can be deleted, but the most common form of inactivation is through point mutations, with the most common mutations occurring in the substrate recognition domain of FBXW7 (REF. 95 ). The substrate-binding domain is composed of a series of WD40 repeats that form an eight-bladed β-propeller structure 98 , and nearly half of the tumour-associated missense mutations result in amino acid substitutions at three key arginine residues within the WD40 domain (Arg465Cys/His, Arg479Leu and Arg505Cys) that form the main substrate recognition contacts. The F-box protein-substrate interface is also subject to mutations in its oncogenic substrates. For example, the phosphodegron of MYC is frequently mutated in Burkitt's lymphoma, resulting in the stabilization of MYC 99, 100 , and mutations that disrupt Notch binding to FBXW7 are found in T-cell acute lymphoblastic leukaemia 96, 101 . Similar to SKP2, FBXW7 is a model for the development of SCF-targeted drugs, but restoring the function of mutated FBXW7 requires different approaches. In the straightforward case of simple deletion, in which FBXW7 is completely absent, the degradation of FBXW7 substrates must be reconstituted, creating a considerable challenge. However, evidence suggests that other ubiquitin ligases could be retargeted to replace the functionality of FBXW7. Proteolysis targeting chimaeras (PROTACs) were originally developed as heterobivalent, chimeric molecules that recruit an E3 ligase with a degron-mimicking compound at one end and recruit a specific target substrate with a compound on the other end, effectively tethering the ligase to the substrate and resulting in target degradation (FIG. 3) . The first reported PROTAC linked the nuclear factor-κB inhibitor-α (IκBα) degron -which is recognized by β-transducin repeat-containing protein (βTrCP; βTrCP1/FBXW1 and βTrCP2/FBXW11, which share biochemical function) -to ovalicin, a drug that covalently binds to methionine aminopeptidase 2 (METAP2) 102, 103 . Thus, this PROTAC targeted METAP2 for SCF βTrCP -mediated degradation 102, 103 . Variations on this theme have been shown to be effective (at least in cell culture model systems), and, in addition to peptide-degron fusions, PROTACS that are entirely based on small molecules have been developed 104 . For example, an androgen receptor ligand was fused to a nutlin to recruit the androgen receptor to the MDM2 ubiquitin ligase 105 . The principle of ubiquitin ligase retargeting received recent validation with the understanding of the biochemical basis for the effectiveness of lenalidomide (a thalidomide derivative) in multiple myeloma treatment. Lenalidomide has been successfully used in the clinic for many years, but its mechanism of action was unknown. Strikingly, lenalidomide binds to cereblon (CRBN), a substrate recognition subunit for a CRL4 ubiquitin ligase complex, forcing CRBN to target the Ikaros transcription factors for ubiquitylation and degradation 106, 107 . Ikaros proteins are essential for the survival of multiple myeloma cells, accounting for the effects of lenalidomide. The recently solved crystal structure of lenalidomide in complex with CRBN shows that lenalidomide binds the substrate-binding domain of CRBN and blocks ubiquitylation of an endogenous CRBN substrate, suggesting that lenalidomide-associated phenotypes may be associated with both inhibition of endogenous substrate degradation and de novo substrate targeting 108 . Notably, although lenalidomide and the other thalidomide derivatives all inhibit ubiquitylation of the homeobox protein MEIS2, Ikaros protein recruitment varies among these compounds. Crystal structures of the CRBN-lenalidomide-Ikaros and CRBN-MEIS2 complexes are likely to be required to fully understand the biochemical mechanisms of lenalidomide. However, our current understanding of the interaction of lenalidomide with CRBN supports the idea that similar strategies can be used to target SCF ubiquitin ligases. Owing to the nature of degron recognition by F-box proteins, which often recognize small chemical modifications, SCF ubiquitin ligases may be particularly amenable to regulation through bivalent small molecules for the restoration of a lost function and/or de novo substrate targeting.
However, in addition to requiring extensive knowledge of both the ubiquitin ligase and the proposed substrate, the retargeting approach to restoring function faces other barriers. For example, a PROTAC that binds and retargets an F-box protein may disrupt the regulation of the normal substrates of that F-box protein or target more than one new substrate, creating off-target effects (although existing PROTACs have not demonstrated this problem so far). Indeed, the side effects of thalidomide are well documented in multiple animal systems 109 . The effects of thalidomide on animal development are mainly due to the binding of CRBN, but the precise biochemical nature of the effect of thalidomide during development (that is, whether thalidomide inhibits the degradation of a normal CRBN substrate or retargets CRBN to an alternative substrate) is unclear 110 . An intermediate approach to restoring the function of mutated F-box proteins has been suggested by the characterization of the Arabidopsis auxin receptor TIR1, which is an F-box protein. TIR1 mediates the degradation of a family of transcription factors via a unique degron composed of the target protein and the hormone auxin. Auxin fills a cavity in the substrate-binding site of TIR1, establishing an additional molecular surface to stabilize the interaction between the substrate and TIR1 (REF. 111) , and this auxin-based system can be reconstituted in mammalian cells, demonstrating proof of concept for compounds that function in a manner similar to auxin 112 . Analogous to auxin, when the binding between an F-box protein and its substrate is disrupted by mutation of the substrate binding domain of the F-box protein, a small molecule may be capable of acting as a 'molecular glue' between the proteins and restoring proper degradation.
The development of auxin-like molecular glue compounds is restricted to substrate-binding surfaces and may not be feasible for all disease-associated mutations of F-box proteins, which could affect the global protein structure. However, small molecules have been effectively used to bind and stabilize the conformation of mutated p53 (specifically the Y220C mutant) 113, 114 . These 'reactivators' act as molecular chaperones by preferentially interacting with the correctly folded conformation of p53 and stabilizing its functional structure. Reactivators that bind F-box proteins outside the substrate-binding domains could stabilize or shift structural elements to restore proper substrate recognition and ubiquitylation.
Because many proteins feature mutation hot spots, a small array of compounds (either auxin-or reactivatorlike) could enable the treatment of a high percentage of patients. For example, a large percentage of FBXW7 mutations occur at three arginine residues in the substrate-binding region, making FBXW7 a prime target for auxin-like therapies that stabilize the binding interface with substrates 95 . Additionally, allosteric inhibitors of yeast Cdc4, the yeast homologue of FBXW7, suggest that compounds that bind outside the substrate-binding interface can positively or negatively affect substrate recruitment, supporting the idea that reactivators can be developed for FBXW7 mutants 71 .
Emerging targets for restorative therapy. More recently, another F-box protein, FBXO11, has been reported to be widely mutated or deleted in cancers, suggesting it acts as a tumour suppressor. FBXO11 deletions or inactivating mutations are observed in ~15% of patients with diffuse large B cell lymphoma (DLBCL) and in DLBCL cell lines. FBXO11 targets the B cell lymphoma 6 protein (BCL6) oncoprotein for degradation, and in B cells, mutations in FBXO11 directly correspond with stabilization of BCL6 (REF. 115 ). Accordingly, FBXO11 mutations occur predominantly in the carbohydratebinding proteins and sugar hydrolases (CASH) repeat domains, the presumptive substrate-binding domain of FBXO11, and block BCL6 binding. Reconstitution of FBXO11 in DLBCL cell lines induced BCL6 degradation and cell death. Although the potential of FBXO11 as a tumour suppressor is highlighted by BCL6 degradation in B cells, FBXO11 mutations are also observed in cancers of the colon, lung, ovary, head and neck, and other lymphomas, implying that FBXO11 functions as a tumour suppressor in other tissues -probably through additional substrates, as BCL6 expression is largely restricted to B cells [116] [117] [118] [119] [120] . CDT2 is also targeted for degradation by FBXO11, and it is overexpressed and/or amplified in Ewing's sarcoma, as well as in breast, liver and gastrointestinal cancers, suggesting that CDT2 is oncogenic 24, 25, [121] [122] [123] [124] [125] . Other, unidentified substrates may also contribute to the tumour-suppressive activity of FBXO11, and remarkably little is known about the biochemical basis of substrate binding by FBXO11 (TABLE 2) . The CDT2 degron is inhibited by phosphorylation, but a BCL6 degron has not been mapped 24, 25 . Furthermore, no structural information is available for FBXO11. Despite this lack of information, FBXO11 remains an attractive potential target for restorative therapies.
Evidence also exists to support a role for FBXO31 and FBXL4 mutations in human disease, suggesting that these F-box proteins will be appropriate for 'restoration of function' therapies. FBXO31 is linked to tumour suppression and to an inherited intellectual disability, whereas FBXL4 is mutated in mitochondrial encephalomyopathy [126] [127] [128] [129] . However, both FBXO31 and FBXL4 are emerging targets; only a few substrates have been proposed for each, and the relationships of these substrates to the human disorders are unclear. Additionally, little is known about the biochemistry of substrate targeting by either FBXO31 or FBXL4, preventing the rational design of therapies that are targeted against these F-box proteins (TABLE 2) .
Alternative models for inhibiting F-box protein function. Notably, although we have focused on the efforts to develop therapies based on F-box proteins with singular biological functions, the effectiveness of bortezomib and MLN4924 also support the idea that broad inhibition of degradation can be an effective strategy for cancer chemotherapy, especially when applied in a targeted manner to specific diseases and/or patients. Therefore, F-box proteins with a large number of substrates in biologically diverse pathways or F-box proteins with key functions in particular tissues may be suitable targets, although the therapeutic window may be small. These concepts are illustrated by two of the best-characterized F-box proteins: βTrCP and FBXW7.
βTrCP targets a diverse array of substrates in multiple biological pathways, including β-catenin, IκBα (and other IκB proteins), CDC25A, EMI1 (also known as FBXO5), programmed cell death 4 (PDCD4), BIMEL (also known as BCL2L11), Claspin and Period 5 . The diversity of βTrCP substrates is supported, in part, by use of a phosphodegron, typically the motif DSGXXS, with both serine residues phosphorylated. The regulation of βTrCP binding by phosphorylation of the degron allows stimulus-specific degradation. When glycogen synthase kinase 3 (GSK3) is active, β-catenin is degraded and IκBα remains stable. Conversely, when the nuclear factor-κB kinase (IKK) complex is active, IκBα is degraded and β-catenin remains stable. βTrCP itself seems to be constitutively expressed and active.
Many βTrCP substrates are important in human pathologies. β-catenin and CDC25A, among others, are oncogenes, whereas IκBα, PDCD4 and BIMEL, among others, are tumour suppressors 5 . Additionally, Period regulates circadian rhythms. All of these proteins are deregulated in various disorders, highlighting the difficulty of generating a single outcome via inhibition of βTrCP. However, there are several justifications to explore inhibition of βTrCP function as a therapy. With specific molecular genetic knowledge of a disease, βTrCP inhibitors could be applied in a targeted manner. For example, many B cell malignancies are dependent on active nuclear factor-κB (NF-κB) signalling for their survival 130 , and inhibition of βTrCP would increase IκB levels, decreasing this survival signalling 131 . βTrCP inhibition could also induce apoptosis through BIMEL stabilization in cancers with activated mitogen-activated protein kinase pathways 132 . Alternatively, the sheer breadth and importance of βTrCP substrates in regulating the core cell cycle could be exploited. Silencing βTrCP also sensitizes cells to genotoxic stress 133 and inhibition of βTrCP has the potential to arrest the cell cycle at multiple points, which could lead to the death of proliferating tumour cells. Indeed, inhibitors of βTrCP that are effective at nanomolar concentrations have been developed; these inhibitors efficiently blocked the proliferation of breast and prostate cancer cells (N. Wilkie, personal communication, and the UB Pharma website (see Further information)).
Beyond generating direct inhibitors of βTrCP, it may also be possible to exploit the regulation of the βTrCP phosphodegron by kinases. The inhibition of a specific kinase could block the degradation of one substrate while leaving the degradation of another substrate unaffected. Notably, this approach has been proposed for manipulation of one FBXW7 substrate. Although FBXW7 is known primarily as a tumour suppressor 60 , in the B cell lineage, it serves as a pro-survival factor through the degradation of the p100 protein (encoded by NFκB2) 76 . Stabilization of p100 in B cells leads to decreased cell survival and proliferation. Similar to βTrCP, FBXW7 targets substrates using a phosphodegron, and the p100 degron is phosphorylated by GSK3. Blocking this phosphorylation of the p100 degron by GSK3 stabilizes p100 and blocks B cell proliferation, highlighting the potential to indirectly inhibit F-box-dependent degradation by preventing substrate modification.
FBXW7 also highlights another context-specific use of F-box protein inhibitors. Although inhibition of a tumour suppressor seems an unusual treatment for cancer, the inhibition of FBXW7 has been proposed as an approach to sensitize cancer stem cells to chemotherapies 91, [134] [135] [136] . For example, in chronic myelogenous leukaemia, imatinib (Gleevec or Glivec; Novartis) is a highly effective therapy that can kill most of the cancerous cells, but it fails to kill the cancer-initiating cells in the bone marrow, which are often quiescent 137 . Upon discontinuation of therapy, the cancer can return, and this cancer-initiating cell population is a reservoir that facilitates the acquisition of inhibitor resistance mutations. Consequently, forcing these cancer stem cells out of quiescence and into the cell cycle should make them more susceptible to chemotherapy, which differentially affects proliferating cells 134 . Indeed, in experimental genetic systems, deletion of Fbxw7 in a mouse model of chronic myelogenous leukaemia facilitates the eradication of these leukaemia-initiating cells by tyrosine kinase inhibitor therapies. This effect seems to be largely dependent on increases in MYC levels, suggesting that inhibition of MYC degradation by FBXW7 or universal FBXW7 inhibition might synergize with existing chemotherapies 135, 137 . Whether this approach can be adapted to patients remains unclear, as are the long-term effects of FBXW7 inhibition.
Future perspectives
A disproportionately large effort has been put into the research of a small number of well-characterized F-box proteins. However, even these few F-box proteins have demonstrated that the number of diverse pathways that exploit SCF-mediated proteolysis is large. By contrast, the majority of F-box proteins remain functionally mysterious or 'orphans' , with no established substrates, and our lack of understanding of these orphans is a primary impediment to the development of novel F-box protein-targeted therapies. Ideal F-box proteins for targeted therapies should have defined biological roles in disease, multiple substrates, defined biochemical mechanisms and a crystal structure, and although our knowledge of F-box proteins is expanding rapidly, research into many of these proteins is just beginning. Undoubtedly, as the substrates and functions of these orphan F-box proteins are elucidated, additional drug targets will become apparent. Importantly, even for those F-box proteins with well-defined biochemistry and known structures, more functional and structural data are required to facilitate the development of effective therapies. Finally, as we enter an era when it is possible to know the unique molecular genetic signature of an individual's disease, there is substantial promise in the situational or context-dependent application of inhibitors of SCF complexes.
Historically, the SCF field has focused on the role of F-box proteins in cancer, but it is evident that F-box proteins influence many aspects of biology beyond cell proliferation and survival. Moving forward, research into non-cancer disorders, such as sleep, mood, metabolic and intellectual disability disorders, will be required to fully define the role of the F-box family of proteins in disease and uncover potential drug targets. However, as exemplified by the established F-box proteins discussed in this Review, with the proper information in hand, many different approaches are available to manipulate substrate degradation for therapeutic applications.
